{"id":"W3172867079","doi":"10.1200/jco.2021.39.15_suppl.1004","title":"Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Clinical endpoint; Ven; Fulvestrant; Venetoclax; Oncology; Progression-free survival; Neutropenia; Estrogen receptor; Phases of clinical research; Gastroenterology; Cancer; Breast cancer; Chemotherapy; Randomized controlled trial; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00405477,0.0004544026,0.005434746,0.0002112936,0.00006980739,0.00001254723,0.0003575705,0.0003708651,0.0008669699],"category_scores_gemma":[0.009666689,0.0003313536,0.000769686,0.0005776109,0.000801088,0.0003419219,0.0001610851,0.001912847,0.000006904411],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008969576,"about_ca_system_score_gemma":0.008731761,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005051652,"about_ca_topic_score_gemma":0.003727282,"domain_scores_codex":[0.9890728,0.002975012,0.005952087,0.0006825973,0.0008066351,0.0005108664],"domain_scores_gemma":[0.9774518,0.01555101,0.004218464,0.0005236435,0.001708519,0.0005465549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8209911,0.01292655,0.0002231386,0.00005111197,0.004222126,0.00327541,0.001419636,0.001683352,0.0022167,0.00001669862,0.0001114297,0.1528628],"study_design_scores_gemma":[0.9292941,0.04906695,0.005844117,0.00121195,0.002219428,0.0005629414,0.00348852,0.0002150714,0.002307912,0.0003197209,0.005126675,0.0003426163],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889971,0.002807212,0.0003275825,0.003967434,0.001824378,0.001245712,0.0006287035,0.0000176925,0.0001841932],"genre_scores_gemma":[0.9763542,0.002280246,0.01938451,0.0006437764,0.0008888216,0.00008345478,0.00003756587,0.00006664048,0.000260816],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1525201,"threshold_uncertainty_score":0.9999139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08351404281916895,"score_gpt":0.4545891997308339,"score_spread":0.371075156911665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}